Treatment Options

4 FDA-approved systemic regimens, surgery for select early-stage epithelioid patients, and 10+ actively enrolling clinical trials define the 2026 mesothelioma treatment landscape. First-year billed costs typically run $150,000–$1,000,000+ for a combined immunotherapy, surgery, and supportive-care course. Average legal settlements of $1,000,000–$1,400,000 are the single largest source of funding patients use to cover those costs. Free case evaluations are available 24/7 from Danziger & De Llano at (855) 699-5441.

Mesothelioma Treatment Cost Facts (verified 2026-05-13)

Treatment cost row	2026 cost range (United States)	Notes
First-year cost	$150,000–$1,000,000+	Total typical first-year billed cost combining diagnosis, surgery, immunotherapy or chemotherapy (chemo), supportive care, and follow-up imaging.
Immunotherapy / year	$150,000–$200,000	Annual cost of FDA-approved immunotherapy — nivolumab + ipilimumab (Nivo+Ipi), the CheckMate 743 regimen approved March 2022 for unresectable malignant pleural mesothelioma (MPM).
Surgery (P/D)	$30,000–$100,000+	Pleurectomy/decortication (P/D) procedural cost; extrapleural pneumonectomy (EPP) costs are similar or higher.
Chemotherapy course	$10,000–$30,000 per cycle	Standard cisplatin/pemetrexed (Pem+Cis) course; a typical full course is 4–6 cycles, so total course cost is roughly $40,000–$180,000.
Average settlement	$1,000,000–$1,400,000	Average mesothelioma civil lawsuit settlement (Mealey's industry benchmark). Trial verdicts range higher.

Executive Summary

Mesothelioma treatment in 2026 follows a histology-driven algorithm. Pemetrexed + platinum chemotherapy has been the backbone since FDA approval in 2004 based on the EMPHACIS Phase III trial, which demonstrated a median overall survival (OS) of 12.1 months versus 9.3 months with cisplatin alone (hazard ratio [HR] for death 0.77).

In October 2020, the FDA approved nivolumab + ipilimumab (Nivo+Ipi) for unresectable MPM based on CheckMate 743, the first Phase III trial to show an immunotherapy regimen extending survival over chemotherapy in this disease. CheckMate 743 reported median OS of 18.1 months with Nivo+Ipi versus 14.1 months with chemotherapy (HR 0.74; 96.6% confidence interval [CI] 0.60–0.91; p = 0.002). Three-year follow-up confirmed durable benefit, with 23% of patients on Nivo+Ipi alive at 3 years versus 15% on chemotherapy.

Surgery is reserved for early-stage epithelioid disease at multidisciplinary centers of expertise; pleurectomy/decortication (P/D) is preferred over extrapleural pneumonectomy (EPP) in current guidelines. For peritoneal mesothelioma, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard of care in eligible patients and produces dramatically better outcomes than systemic therapy alone — multi-institutional registries report median OS of 38–53 months with 5-year OS of 39–47% in selected patients.

The economic burden is severe. With first-year billed costs typically $150,000–$1,000,000+, most U.S. mesothelioma patients rely on a combination of insurance, asbestos trust fund recoveries, and civil settlements averaging $1,000,000–$1,400,000 to fund a full course of care.

Key Facts

• Mesothelioma is a rare, asbestos-caused cancer. The Global Burden of Disease 2019 analysis estimated 34,511 incident cases globally in 2019 (95% uncertainty interval 31,199–37,771) and 29,251 deaths, with occupational asbestos exposure contributing 85.2% of disability-adjusted life years (DALYs).
• Asbestos exposure is the established cause of mesothelioma — cumulative occupational, environmental, household-secondary, and military exposures account for the disease worldwide.
• Histologic subtype is the strongest prognostic factor. Epithelioid mesothelioma carries the longest median survival; sarcomatoid is the most aggressive; biphasic falls between them.
• 4 FDA-approved systemic options anchor 2026 first-line care: pemetrexed + cisplatin (2004), nivolumab + ipilimumab (2020), pembrolizumab + pemetrexed + platinum (2024), and tumor treating fields (TTFields) under Humanitarian Device Exemption (HDE) with chemotherapy (2019).
• Surgery is restricted to early-stage (clinical Stage I–IIIA) epithelioid disease evaluated at a high-volume mesothelioma center; sarcomatoid histology is a contraindication to maximal cytoreduction.
• Pleurectomy/decortication (P/D) is preferred over extrapleural pneumonectomy (EPP) for pleural disease in 2026 NCCN and ASCO guidance.
• CRS + HIPEC is the standard surgical approach for peritoneal mesothelioma in eligible patients and produces 5-year OS of 39–47% in multi-institutional series.
• Compensation funding — civil settlements averaging $1,000,000–$1,400,000, asbestos trust fund payouts, and Veterans Affairs (VA) disability are the primary mechanisms patients use to cover the $150,000–$1,000,000+ first-year cost. Free legal evaluation: Danziger & De Llano at (855) 699-5441.

What FDA-approved systemic therapies exist for mesothelioma in 2026?

Four systemic regimens are FDA-approved for mesothelioma as of 2026. Three carry standard approvals based on Phase III randomized trials; the fourth (TTFields) is approved under the Humanitarian Device Exemption (HDE) pathway, which the FDA reserves for rare conditions affecting fewer than 8,000 U.S. patients per year and which does not require demonstration of effectiveness to the standard of premarket approval (PMA).

Pemetrexed + cisplatin (Pem+Cis), 2004 — the chemotherapy backbone

The pivotal EMPHACIS Phase III trial randomized 456 chemotherapy-naïve patients with malignant pleural mesothelioma to pemetrexed + cisplatin versus cisplatin alone. Pemetrexed + cisplatin produced a median OS of 12.1 months versus 9.3 months for cisplatin (HR 0.77; p = 0.020), an objective response rate (ORR) of 41.3% versus 16.7%, and a median time to progression of 5.7 versus 3.9 months. The combination became the standard first-line chemotherapy and remains the backbone for patients who are not candidates for immunotherapy.

In current practice, carboplatin is frequently substituted for cisplatin in older patients or those with reduced renal function, with broadly comparable efficacy in clinical use.

Nivolumab + ipilimumab (Nivo+Ipi), 2020 — first-line immunotherapy

The FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for first-line treatment of unresectable malignant pleural mesothelioma on October 2, 2020. Approval was based on CheckMate 743 (NCT02899299), a Phase III open-label trial that randomized 605 patients to nivolumab + ipilimumab versus standard platinum + pemetrexed chemotherapy.

CheckMate 743 endpoint	Nivolumab + ipilimumab (Nivo+Ipi)	Chemotherapy (platinum + pemetrexed)
Median overall survival (OS) — primary	18.1 months (95% confidence interval [CI] 16.8–21.4)	14.1 months (95% CI 12.4–16.2)
Hazard ratio (HR) for death	0.74 (96.6% CI 0.60–0.91); p = 0.002
2-year OS rate	41%	27%
3-year OS rate (follow-up analysis)	23%	15%
Median progression-free survival (PFS)	6.8 months	7.2 months
Objective response rate (ORR)	39.6%	43.0%
Grade 3–4 treatment-related adverse events (AE)	30%	32%

Sources: Baas et al. 2021 (PMID 33485464) and Peters et al. 2022 (PMID 35124183).

The benefit was most pronounced in non-epithelioid (sarcomatoid + biphasic) histology, where median OS reached 18.1 months with Nivo+Ipi versus 8.8 months with chemotherapy. In epithelioid disease, the median OS difference was smaller (18.7 vs. 16.5 months). The FDA's first-line approval covers both histologic groups, but guidelines now recommend Nivo+Ipi as the preferred first-line option for non-epithelioid disease and as an alternative in epithelioid disease.

Pembrolizumab + pemetrexed + platinum (Pembro+Pem+Plat), 2024

The FDA approved pembrolizumab (Keytruda) in combination with pemetrexed and platinum chemotherapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024, based on the CCTG IND.227/KEYNOTE-483 randomized Phase 2/3 trial. The approval is a U.S. regulatory fact documented on the FDA's drug-approval page; published efficacy data from the trial sit outside the verified-citation pool used for this article and are therefore not summarized here. Patients considering this regimen should discuss the most recent published outcome data with their treating oncologist and consult the FDA approval label.

Tumor treating fields (TTFields) + chemotherapy, 2019 — Humanitarian Device Exemption (HDE)

The NovoTTF-100L System (now marketed as Optune Lua) received FDA approval on May 23, 2019, under the HDE pathway for use concurrently with pemetrexed and platinum-based chemotherapy in adult patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma. The HDE pathway is reserved for rare conditions and does not require demonstration of effectiveness equivalent to the standard PMA process; the FDA's own approval documentation includes the caveat that "the effectiveness of this device for this use has not been demonstrated."

When is surgery appropriate for mesothelioma?

Surgery for malignant pleural mesothelioma is reserved for a narrow population: clinical Stage I disease, epithelioid histology, no nodal involvement (N0), adequate cardiopulmonary reserve, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1. Sarcomatoid histology is an absolute contraindication to maximal cytoreductive surgery in current National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) 2025 guidance.

The two principal pleural cytoreductive operations are pleurectomy/decortication (P/D) — surgical removal of the parietal and visceral pleura with preservation of the underlying lung — and extrapleural pneumonectomy (EPP) — en-bloc removal of the pleura, ipsilateral lung, ipsilateral diaphragm, and pericardium. NCCN now recommends P/D over EPP when surgery is performed.

Surgical comparison	Pleurectomy/decortication (P/D)	Extrapleural pneumonectomy (EPP)
Lung-sparing	Yes — preserves ipsilateral lung	No — removes ipsilateral lung
30-day mortality (expert centers)	0–4%	4–15%
90-day mortality (expert centers)	~4%	9–11%
Quality of life at 6 months post-operative	Better preserved	More compromised
2026 NCCN preference	Preferred for cytoreductive surgery	Reserved for highly selected cases at centers of excellence

The phase III MARS2 UK trial (published Lancet Respiratory Medicine, 2024) randomized patients with resectable pleural mesothelioma to extended P/D plus chemotherapy versus chemotherapy alone and reported worse survival in the surgical arm (median OS 19.3 vs. 24.8 months) along with significantly more serious adverse events (SAEs). The MARS2 results moved NCCN and ASCO 2025 toward more conservative surgical patient selection. Detailed published efficacy data from MARS2 sit outside the verified-citation pool used for this article; patients evaluating surgery should review the most recent published trial data with their multidisciplinary surgical team.

How is peritoneal mesothelioma treated with CRS + HIPEC?

Peritoneal mesothelioma — mesothelioma of the abdominal lining — has a fundamentally different treatment paradigm from pleural disease. The standard of care for eligible patients is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), performed at high-volume specialty centers.

CRS removes all visible tumor from the peritoneal cavity. Immediately after resection, heated chemotherapy (typically cisplatin or cisplatin + doxorubicin at ~42°C) is circulated through the abdomen for 60–90 minutes to kill microscopic residual disease.

CRS + HIPEC outcome series	Patients (n)	Median overall survival (OS)	5-year OS
Yan et al. 2009 — multi-institutional registry, 8 institutions (PMID 19917862)	405	53 months	47%
Helm et al. 2015 — systematic review and meta-analysis (PMID 25124472)	1,047 (pooled across 20 studies)	29–92 months (range across series)	39% (pooled estimate)

Sources: Yan et al. 2009 multi-institutional registry; Helm et al. 2015 systematic review and meta-analysis.

Key prognostic factors across CRS + HIPEC series:

• Histology — epithelioid disease has substantially better outcomes than biphasic; sarcomatoid is generally a contraindication.
• Completeness of cytoreduction (CC) score — CC-0 (no visible residual disease) or CC-1 (residual ≤2.5 mm) yields markedly better survival than CC-2 or CC-3.
• Peritoneal cancer index (PCI) — a measure of disease burden; lower PCI predicts better outcomes.
• Lymph node involvement — absence of lymph node disease is associated with longer survival.

CRS + HIPEC is offered at a limited number of U.S. centers with formal mesothelioma programs. Patients diagnosed with peritoneal mesothelioma should request referral to a high-volume center for surgical evaluation before starting systemic chemotherapy when feasible.

What is the role of immunotherapy in mesothelioma?

Immunotherapy is now a foundational component of mesothelioma treatment after the 2020 approval of nivolumab + ipilimumab (Nivo+Ipi) and the 2024 approval of pembrolizumab + pemetrexed + platinum (Pembro+Pem+Plat) added a second checkpoint-inhibitor regimen.

In second-line and later settings, the INITIATE Phase 2 single-arm trial evaluated nivolumab + ipilimumab in patients with recurrent malignant pleural mesothelioma after prior platinum-based chemotherapy. INITIATE reported a disease control rate (DCR) of 68% at 12 weeks and a partial-response rate of 29%, supporting the role of dual checkpoint blockade in the post-chemotherapy setting.

Per the 2025 ASCO guideline and NCCN 2026 update, programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and microsatellite instability (MSI) status should not be used to guide first-line treatment selection in mesothelioma — magnitude of benefit in CheckMate 743 was similar across PD-L1 levels.

What active clinical trials are enrolling mesothelioma patients in 2026?

Multiple investigational regimens are in active clinical-trial enrollment as of 2026, spanning targeted therapy, novel immunotherapy combinations, and cellular therapy. The following table lists representative actively enrolling U.S. trials by ClinicalTrials.gov (NCT) registration; full eligibility and site information is available at clinicaltrials.gov.

Trial / agent	ClinicalTrials.gov number (NCT)	Phase	Mechanism / approach
VT3989 (Vivace Therapeutics) — Tumor Endothelial Marker, Adhesion Molecule (TEAD) inhibitor	NCT04665206	Phase 1/2 → Phase 3 planned 2026	Pan-TEAD palmitoylation inhibitor; targets the Hippo–YAP/TAZ–TEAD pathway downstream of the NF2 (neurofibromin 2) tumor suppressor.
Pegargiminase (ADI-PEG 20) + chemotherapy — ATOMIC-Meso	NCT02709512	Phase 2/3 complete; Biologics License Application (BLA) under FDA review	Pegylated arginine deiminase; depletes circulating arginine in tumors lacking argininosuccinate synthetase 1 (ASS1).
MSK intrapleural mesothelin Chimeric Antigen Receptor T-cell (CAR-T) — M28z1XXPD1DNR	NCT04577326	Phase 1	Autologous mesothelin-targeted CAR-T cells with dominant-negative PD-1 receptor (PD1DNR), instilled directly into the pleural space.
NCI TNhYP218 mesothelin CAR-T	NCT06885697	Phase 1	Mesothelin-targeted CAR-T cells derived from T naïve / stem cell memory (TNSCM) cells; intravenous (IV) infusion.
EVEREST-2 — A2B694 logic-gated Tmod CAR-T (A2 Biotherapeutics)	NCT06051695	Phase 1/2	Two-receptor "logic-gated" CAR-T: activated by mesothelin, blocked by HLA-A*02 to spare normal mesothelial tissue.
STAR-101 — SynKIR-110 KIR-CAR (Verismo Therapeutics)	NCT05568680	Phase 1	Mesothelin-targeted T-cell therapy using a multi-chain killer immunoglobulin-like receptor (KIR)-based chimeric antigen receptor.
Volrustomig (MEDI5752) — eVOLVE-Meso	NCT06097728	Phase 3	Bispecific antibody targeting both PD-1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) in a single molecule; tested with carboplatin + pemetrexed.
Sacituzumab govitecan — TROP-2 antibody-drug conjugate (ADC)	NCT06477419	Phase 2	Trophoblast cell-surface antigen 2 (TROP-2)-targeted ADC delivering SN-38 cytotoxic payload to mesothelioma cells.
TIGER Meso — TTFields real-world outcomes	NCT05538806	Observational (post-authorization)	Real-world data collection on tumor treating fields (TTFields) plus chemotherapy in U.S. mesothelioma patients.
HIT-Meso — high-dose proton beam therapy (UCL / Asthma + Lung UK)	Registered (UK; ISRCTN)	Phase 3	Proton beam radiation therapy at 50–60 Gy after surgery; comparator arm receives standard photon radiation.

Trial details are summarized from publicly available ClinicalTrials.gov registrations; published efficacy data for these investigational agents sit outside the verified-citation pool used for this article and should be reviewed with a treating oncologist.

How much does mesothelioma treatment cost?

The economic burden of mesothelioma treatment in the United States is severe and concentrated in the first year after diagnosis.

• First-year billed cost — $150,000–$1,000,000+ covering diagnosis, surgery (when indicated), 4–6 cycles of chemotherapy, immunotherapy, supportive care, and follow-up imaging.
• Immunotherapy (Nivo+Ipi) per year — $150,000–$200,000 for the FDA-approved nivolumab + ipilimumab regimen at standard dosing.
• Pleurectomy/decortication (P/D) — $30,000–$100,000+ for the procedural component; EPP is similar or higher.
• Standard chemotherapy (Pem+Cis) per cycle — $10,000–$30,000, so a typical 4–6 cycle course is roughly $40,000–$180,000.

All cost figures sourced from D&D house-default cost-facts box, verified 2026-05-13. See cost-facts table at the top of this article.

These are billed costs; out-of-pocket exposure depends on insurance coverage, network status, and whether patients have access to clinical-trial-funded treatment. Even with comprehensive coverage, mesothelioma patients commonly face deductibles, copay maximums, and non-covered services that produce five-figure out-of-pocket spending in the first year.

How can compensation help cover mesothelioma treatment costs?

Most U.S. mesothelioma patients fund treatment through some combination of insurance and one or more of the following compensation pathways:

• Civil settlements and verdicts — average mesothelioma settlements run $1,000,000–$1,400,000; trial verdicts can be substantially higher. Danziger & De Llano handles mesothelioma claims nationwide; free case evaluation is available at (855) 699-5441.
• Asbestos trust funds — more than 60 trusts hold an aggregate of approximately $30 billion to compensate victims of bankrupt asbestos manufacturers. Each trust has its own claim procedure and payment schedule; an attorney experienced in trust filings can identify which trusts a particular work or exposure history qualifies for.
• Veterans Affairs (VA) disability compensation — veterans whose mesothelioma is service-connected qualify for VA disability at the 100% rating level, which produces monthly tax-free compensation; survivors may qualify for Dependency and Indemnity Compensation (DIC). See the veterans mesothelioma claims page for filing procedure.
• Workers' compensation — for occupational exposures, state workers' compensation systems may cover medical expenses and a portion of lost wages, though most occupational mesothelioma cases also have viable third-party product-liability claims that pay substantially more than workers' comp alone.
• Insurance and Medicare — private insurance, Medicare, and Medicaid cover most direct medical costs but rarely cover the full economic impact of treatment, lost wages, and caregiver burden.

For a free, no-obligation review of which of these pathways fit a particular case, contact Danziger & De Llano at (855) 699-5441.

Where can mesothelioma patients find centers of expertise?

Outcomes in mesothelioma — both surgical and systemic — are strongly correlated with center experience. Patients should request referral to a high-volume mesothelioma program for diagnostic confirmation, multidisciplinary treatment planning, and surgical evaluation when applicable.

Examples of academic and community programs with established mesothelioma services include Memorial Sloan Kettering (New York), MD Anderson Cancer Center (Houston), Brigham and Women's Hospital (Boston), University of Pennsylvania, Moffitt Cancer Center (Tampa), Wake Forest Baptist (Winston-Salem), and the National Cancer Institute (Bethesda). The full list of National Cancer Institute (NCI)-designated cancer centers is available at cancer.gov/research/infrastructure/cancer-centers; not every NCI-designated center has a high-volume mesothelioma program, so patients should specifically ask whether the center has a dedicated mesothelioma multidisciplinary team.

Additional patient resources:

• Mesothelioma treatment costs — detailed breakdown
• Mesothelioma prognosis and survival
• Asbestos exposure and legal claims
• Veterans mesothelioma claims and VA benefits
• Compare mesothelioma settlement outcomes — Danziger & De Llano

Free case evaluation

Danziger & De Llano represents mesothelioma patients and their families nationwide. A case evaluation is free and does not commit a patient or family member to filing a claim. Call (855) 699-5441 24/7 or visit dandell.com to start a confidential review with an attorney who handles mesothelioma cases full-time.